Treatment outcomes in cytomegalovirus anterior uveitis
1
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85197443685
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Boonhaijaroen T., Choopong P., Tungsattayathitthan U., Tesavibul N., Sanphan W., Boonsopon S. Treatment outcomes in cytomegalovirus anterior uveitis. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-66224-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/99608
Title
Treatment outcomes in cytomegalovirus anterior uveitis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
This retrospective cohort study investigated patients with cytomegalovirus anterior uveitis (CMV AU) and compared treatment outcomes between regional and systemic antiviral therapies. Treatment modalities included topical (2% ganciclovir [GCV] eye drops or 0.2% GCV eye gel) and systemic (intravenous GCV or oral valganciclovir) groups. The comparison parameters included response rates, time to response, recurrence rates, time to recurrence, and complications. Forty-four patients (54.5% male) with a mean age of 56 ± 9.87 years were enrolled, with 31 eyes in the topical group and 13 eyes in the systemic group. The median response time was significantly slower in the topical group (63 days [IQR 28–112]) compared to the systemic group (28 days [IQR 24–59]) (p = 0.04). Treatment response rates were 87.1% (27/31) in the topical group and 100% (13/13) in the systemic group (p = 0.30), while recurrence rates were 37% (10/27) and 69.2% (9/13) (p = 0.056), with a median time to recurrence of 483 days [IQR 145–1388] and 392 days [IQR 203.5–1907.5] (p = 0.20), respectively. In conclusion, both topical and systemic GCV treatments demonstrated favorable outcomes for CMV AU. Systemic GCV showed rapid control of intraocular inflammation.